BAGSVAERD, Denmark, Jan. 2, 2015 (GLOBE NEWSWIRE) -- In continuation of the company's announcements dated 30 January 2014 and 30 October 2014 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2014 owned 56,807,153 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 11,361,431 or 2.1% of the total share capital.
In the fourth quarter of 2014 a total of 13,914,000 B shares were repurchased, and 383,136 B shares were disposed of to employees in connection with employee incentive programmes.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
|Anne Margrethe Hauge||+45 3079 email@example.com|
|Kasper Roseeuw Poulsen||+45 3079 firstname.lastname@example.org|
|Daniel Bohsen||+45 3079 email@example.com|
|Melanie Raouzeos||+45 3075 firstname.lastname@example.org|
|Frank Daniel Mersebach (US)||+1 609 235 email@example.com|
Company announcement No 1 2015 http://hugin.info/2013/R/1884197/665641.pdf
Source:Novo Nordisk A/S